NLRP3 inflammasome inhibitors are described in a Zomagen Biosciences Ltd. patent and are reported to be useful for the treatment of autoimmune, cardiovascular, inflammatory, liver, lung, metabolic and ...

Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, College of Chemistry and Materials, Fudan ...

1 Laboratory of Regenerative Medicine, Medical University of Warsaw, Warsaw, Poland 2 Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY, United States ...

Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, China ...

The NLRP3 inflammasome, a key mediator of neuroinflammation, has emerged as a critical player in AD pathogenesis, contributing to the accumulation of β-amyloid (Aβ) plaques, tau hyperphosphorylation, ...

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01 ...

The new SAB members have made vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation, and are at the forefront of clinical development in ...